Author

M. Kim

Institution: UCB Pharma (United States)

Observed institution: UCB Pharma (United States)

OpenAlex ID: A5083424317

Pos0229 Disease Activity and Inflammation Following Withdrawal of Certolizumab Pegol Treatment in Axial Spondyloarthritis Patients Who Did Not Experience Flares During the C-optimise Study

2021 · L.S. Gensler, X. Baraliakos, et al. · Annals of the Rheumatic Diseases · 2

Pos0864 Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus Asdas Inactive Disease in Patients With Active Axial Spondyloarthritis Treated With Bimekizumab: 52-week Results From Two Phase 3 Studies

2025 · M. Rudwaleit, H. Marzo-Ortega, et al. · Annals of the Rheumatic Diseases

Ab0913 Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared With Standard Non-biologic Treatment: a Matched Control Study in High-risk Patients With Axial Spondyloarthritis

2024 · N. Haroon, Z. Baskurt, et al. · Annals of the Rheumatic Diseases

PBI5 An Indirect Comparison of Sustained Remission and FLARE Rates in Responders with NON-Radiographic Axial Spondyloarthritis (NR-AXSPA)

2020 · S. Kiri, M. Kim, et al. · Value in Health

Works count: 4

Citation count: 2

H-index: 1

I10-index: